Anti-inflammatory compositions and methods of use

Abstract

The present invention is directed to pharmaceutical compositions containing active compounds, which inhibit the activity of the chemokines, MIP-1α and RANTES. It also is directed to methods of treating inflammatory and immunoregulatory disorders and diseases using these pharmaceutical compositions.

1 . (canceled)  
   
   
       2 . (canceled)  
   
   
       3 . (canceled)  
   
   
       4 . (canceled)  
   
   
       5 . (canceled)  
   
   
       6 . (canceled)  
   
   
       7 . (canceled)  
   
   
       8 . A method of inhibiting the binding of a chemokine, which is MIP-1α or RANTES, to a CCR1 receptor, comprising contacting the composition of  claim 10  with a cell that expresses the CCR1 receptor for a time sufficient to inhibit the binding of the chemokine to the CCR1 receptor.  
   
   
       9 . A method of treating an inflammatory disease, comprising administering a therapeutically effective amount of the composition of  claim 10  to a patient in need thereof for a time sufficient to treat the inflammatory disease.  
   
   
       10 . A composition comprising a pharmaceutically acceptable carrier and a compound of the formula:  
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
   
   
       11 . A method of inhibiting the binding of a chemokine to a chemokine receptor, comprising contacting the composition of  claim 10  with a cell that expresses the chemokine receptor for a time sufficient to inhibit the binding of the chemokine to the chemokine receptor.